Anti‐epidermal growth factor receptor monoclonal antibodies in cancer therapy
暂无分享,去创建一个
F. De Vita | F. Ciardiello | E. Martinelli | R. De Palma | M. Orditura | F. De Vita | E. Martinelli | R. De Palma | M. Orditura | F. Ciardiello | F. Vita | R. D. Palma
[1] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[2] J. Hsuan,et al. EGF receptors as transcription factors: ridiculous or sublime? , 2001, Nature Cell Biology.
[3] C. Bokemeyer,et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study , 2007 .
[4] A. Gingras,et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. , 1998, Genes & development.
[5] L. Schwartz,et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Woodburn,et al. The epidermal growth factor receptor and its inhibition in cancer therapy. , 1999, Pharmacology & therapeutics.
[7] R. Amado,et al. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice , 2007, Nature Biotechnology.
[8] J. Baselga,et al. Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) , 2008 .
[9] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Silvia Benvenuti,et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.
[11] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Swerlick,et al. Transforming growth factor‐α‐induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP‐2‐dependent DNA binding and transactivation , 1997, The EMBO journal.
[13] G. Bar-Sela,et al. Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. , 2007, Current pharmaceutical design.
[14] J. Herman,et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Edward S. Kim,et al. Epidermal growth factor receptor biology (IMC-C225) , 2001, Current opinion in oncology.
[16] C. Köhne,et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial , 2007 .
[17] H. Grabstald,et al. Renal‐cell cancer , 1966, CA: a cancer journal for clinicians.
[18] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[19] C. Dinney,et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] J. Berlin,et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. , 2007, Clinical colorectal cancer.
[21] John Mendelsohn,et al. The EGF receptor family as targets for cancer therapy , 2000, Oncogene.
[22] M. Barbacid,et al. RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.
[23] K. Makino,et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.
[24] J. Berlin,et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Andrew W. Pawluczkowycz,et al. Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes1 , 2008, The Journal of Immunology.
[26] Seta Shahin,et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] L. Mayo,et al. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[28] Muffy Calder,et al. When kinases meet mathematics: the systems biology of MAPK signalling , 2005, FEBS letters.
[29] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[30] M. Aapro,et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Hecht,et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] F. J. Ramos,et al. Monoclonal antibodies in the treatment of advanced colorectal cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[33] R. Herrmann,et al. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] E. Van Cutsem,et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] G. Virella. Humoral immune response. , 1990, Immunology series.
[36] E. Joly,et al. What is trogocytosis and what is its purpose? , 2003, Nature Immunology.
[37] Y. Yarden. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.
[38] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[39] L. Rose,et al. Dermatological toxicities of panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC) from three clinical studies , 2007 .
[40] J. Berlin,et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC) , 2005 .
[41] M. Lindorfer,et al. Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving1 , 2008, The Journal of Immunology.
[42] N. Hanna,et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] N. Normanno,et al. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. , 2003, Endocrine-related cancer.
[44] G. Tortora,et al. EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.
[45] Richard L Schilsky,et al. Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.
[46] Cathleen Brdlik,et al. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. , 2008, The Journal of clinical investigation.
[47] Jonathan P Butchar,et al. The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor–Positive Tumor Cells is Enhanced By Cytokines , 2007, Clinical Cancer Research.
[48] Robert A. Beckman,et al. Antibody-Based Therapy for Solid Tumors , 2008, Cancer journal.
[49] C. Janeway,et al. The Humoral Immune Response , 2001 .
[50] R. Figlin,et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] C. Bokemeyer,et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience , 2008 .
[52] G. Tortora,et al. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. , 2007, Current pharmaceutical design.
[53] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] W. Scheithauer,et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] E. Van Cutsem,et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] G. Giaccone,et al. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[57] E. Joly,et al. Capture of Target Cell Membrane Components via Trogocytosis Is Triggered by a Selected Set of Surface Molecules on T or B Cells1 , 2007, The Journal of Immunology.
[58] T. Seufferlein,et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[59] Silvia Benvenuti,et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.
[60] Sabine Tejpar,et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience , 2008 .
[61] J. Baselga,et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Localizing the EGF receptor , 2002, Nature Cell Biology.
[64] E. Joly,et al. Cutting Edge: CTLs Rapidly Capture Membrane Fragments from Target Cells in a TCR Signaling-Dependent Manner1 , 2001, The Journal of Immunology.
[65] J. Bourhis,et al. Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[67] Larry L. Green,et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice , 1997, Nature Genetics.
[68] I. Pastan,et al. High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy , 2008, Clinical Cancer Research.
[69] R. Figlin,et al. Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies , 2005 .
[70] T. Frebourg,et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.